
Summary for Tradename: atacand
|
|
Latest news for ATACANDResearch finds link between chronic heart failure, iron deficiency2 September 2010, 4:12 am Reportlinker Adds Cardiovascular Generic Drugs: Prospects and Opportunities to 201231 August 2010, 12:19 pm Courtesy of Yahoo News |
| Applicant | Tradename | Generic Name | NDA | Approval Date | Type | RLD | Patent Number | Patent Expiration | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|
| Astrazeneca | ATACAND | candesartan cilexetil | 020838 | Jun 4, 1998 | RX | No | FEB 22,2008 | ||
| Astrazeneca | ATACAND | candesartan cilexetil | 020838 | Jun 4, 1998 | RX | No | MAY 18,2008 | ||
| Astrazeneca | ATACAND | candesartan cilexetil | 020838 | Jun 4, 1998 | RX | No | SEP 13,2005 |
| Drugname | Dosage | Strength | RLD | Submissiondate |
| candesartan cilexetil and hydrochlorothiazide | Tablets | 32 mg/25 mg | Atacand HCT | 3/6/2009 |
| candesartan cilexetil and hydrochlorothiazide | Tablets | 16 mg/12.5 mg and 32 mg/12.5 mg | Atacand HCT | 6/25/2008 |
| candesartan cilexetil | Tablets | 4 mg, 8 mg, 16 mg and 32 mg | Atacand | 12/22/2006 |
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Copyright © 2000-2010, thinkBiotech LLC.